"The Company has now engaged payers that account for 80% of the covered lives in the US and is pleased with the feedback regarding pricing and the relative absence of obstacles for patients to access Sofdra following planned approval"
So the insurers are happy with the feedpack on pricing and patient access, which are huge and important aspects in launching a drug.
Very bullish commentary.
Ann: March 2024 Quarterly Activities Report and Appendix 4C, page-21
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.3¢ |
Change
-0.003(0.85%) |
Mkt cap ! $578.4M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 30.5¢ | 28.3¢ | $2.977M | 10.23M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8136 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 17361 | 1 |
View Market Depth
| Last trade - 15.59pm 17/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |